INNATE PHARMA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.245 EUR | +2.98% |
|
+6.40% | -14.31% |
Chart calendar Innate Pharma
99430006a.qA_N9EKKcLNZxRm8a6wsOVkBkmM-WUra33MStPOQtWA.zDu1mRLEBssbgkHfGO1gfTdkpSxILhqZlDF78b7S-Q7MdZqiGKch-iidSA~b51689a39322816a7c3b6e661838a0cf
Upcoming events on Innate Pharma
Past events on Innate Pharma
| 16/04/2024 | Van Lanschot Kempen conference |
| 10/04/2024 03:00 am | American Association For Cancer Research Meeting - Abstract No: 6582 |
| 26/03/2024 | H.C. Wainwright Cell Therapy Virtual Conference |
| 21/03/2024 06:30 pm | Q4 2023 Earnings Call |
| 21/03/2024 11:30 am | Q4 2023 Earnings Release |
| 12/03/2024 08:50 pm | Leerink Partners Global Biopharma Conference |
| 12/12/2023 08:30 pm | Investor Meeting - Key Opinion Leader |
| 11/12/2023 07:30 am | American Society of Hematology Meeting - Anti-KIR Mab Lacutamab |
| 11/12/2023 07:30 am | American Society of Hematology Meeting - CD123 NK Cell Engager SAR443579 |
| 10/12/2023 04:30 am | American Society of Hematology Meeting - Prof Porcu |
| 28/11/2023 | Investor Day |
| 28/11/2023 | Evercore ISI HealthCONx Conference |
| 15/11/2023 | Jefferies London Healthcare Conference |
| 14/11/2023 06:30 pm | Q3 2023 Sales and Revenue Call |
| 14/11/2023 11:30 am | Q3 2023 Sales and Revenue Release |
| 23/10/2023 12:00 pm | European Society for Medical Oncology Congress - Presentation Number: 854O |
| 22/10/2023 08:00 pm | European Society for Medical Oncology Congress - Presentation Number: 823O |
| 22/10/2023 | European Society for Medical Oncology Congress - Abstract Number: 935P |
| 21/10/2023 | European Society for Medical Oncology Congress - Abstract Number: 1290TiP |
| 23/09/2023 12:52 pm | EORTC Cutaneous Lymphoma Tumour Group Meeting |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million EUR | Released Forecast Spread | 85,8 90,6 -5.28% | 70,5 86,1 -18.16% | 24,7 48,1 -48.67% | 57,7 52,5 9.87% | 61,6 43,4 41.93% | 46,8 |
|
EBITDA Million EUR | Released Forecast Spread | -10,5 -11,3 7.27% | 38,3 -23,5 262.73% | -43,2 -41,7 -3.58% | 29,0 -15,5 287.23% | -7,58 -31,8 76.14% | -18,1 |
|
EBIT Million EUR | Released Forecast Spread | -27,1 -16,3 -65.82% | -18,5 -27,1 31.5% | -47,8 -45,9 -4.11% | -16,4 -21,0 21.88% | -12,7 -34,0 62.74% | -28,1 |
|
Earnings before Tax (EBT) Million EUR | Released Forecast Spread | -20,8 -2,44 -751.59% | -64,0 -22,5 -184.66% | -52,8 -48,0 -9.97% | -58,0 -27,1 -113.71% | -7,57 -26,5 71.41% | -47,1 |
|
Net income Million EUR | Released Forecast Spread | -20,8 -9,95 -108.58% | -64,0 -23,3 -174.11% | -52,8 -43,5 -21.43% | -58,1 -28,7 -102.33% | -7,57 -25,7 70.55% | -25,7 |
|
EPS EUR | Released Forecast Spread | -0,31 -0,14 -124.49% | -0,81 -0,70 -14.92% | -0,66 -0,79 16.53% | -0,73 -0,33 -123.47% | -0,09 -0,30 70.04% | -0,15 |
| Announcement Date | 10/03/20 | 18/03/21 | 24/03/22 | 23/03/23 | 21/03/24 | - |
Quarterly results
| Fiscal Period | December | 2019 S2 | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 | 2025 S1 | 2025 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million EUR | Released Forecast Spread | 26,7 33,7 -20.99% | 36,7 36,7 0.24% | 33,7 57,0 -40.83% | 15,7 28,0 -43.92% | 9,02 22,1 -59.23% | 45,6 41,6 9.53% | 12,1 12,8 -5.34% | 40,2 34,2 17.5% | 21,4 16,8 27.4% | 5,49 | 28,3 | 10,3 | 15,3 |
|
EBIT Million EUR | Released Forecast Spread | -36,5 -21,8 -67.83% | -8,35 -27,4 69.59% | -10,2 -11,1 7.78% | -25,4 -23,8 -7.04% | -22,4 -23,2 3.39% | 8,49 -20,5 141.35% | -24,9 -25,1 0.63% | -0,40 -34,4 98.84% | -12,3 -31,1 60.49% | -28,8 | -19,4 | ||
|
Earnings before Tax (EBT) Million EUR | Released Forecast Spread | -34,0 -19,4 -75.21% | -10,3 -24,5 57.75% | -53,7 -10,5 -412.76% | -23,7 -21,9 -8.11% | -21,8 -24,2 9.91% | 6,38 -21,3 129.99% | -64,3 -37,4 -72.22% | 1,72 -34,5 104.98% | -9,29 -25,7 63.81% | -22,9 | -26,2 | ||
|
Net income Million EUR | Released Forecast Spread | -34,0 -19,8 -71.89% | -10,3 -24,5 57.75% | -53,7 -1,81 -2869.83% | -23,7 -21,9 -8.11% | -29,1 -17,0 -70.66% | 6,30 -21,3 129.65% | -64,4 -41,0 -57.1% | 1,72 -14,1 112.22% | -9,29 -31,1 70.12% | -22,9 | -26,2 | ||
|
EPS EUR | Released Forecast Spread | -0,51 -0,26 -96.15% | -0,30 -0,34 11.76% | -0,36 -0,27 -33.33% | 0,08 -0,25 132% | -0,81 -0,16 -406.25% | 0,02 -0,07 128.57% | -0,11 -0,44 75% | -0,43 | -0,08 | ||||
| Announcement Date | 10/03/20 | 08/09/20 | 18/03/21 | 15/09/21 | 24/03/22 | 15/09/22 | 23/03/23 | 14/09/23 | 21/03/24 | - | - | - | - |
More events
Past sector events for Innate Pharma
| Today | GEMPHARMATECH CO., LTD.: Q1 2024 Earnings Release |
| Today | GEMPHARMATECH CO., LTD.: Q4 2023 Earnings Release |
| 26/04/2024 10:30 am | BB BIOTECH AG: Q1 2024 Earnings Release |
| 26/04/2024 | BIDE PHARMATECH CO., LTD.: Q4 2023 Earnings Release |
| 26/04/2024 | PHARMARESOURCES (SHANGHAI) CO., LTD.: Q1 2024 Earnings Release |
| 26/04/2024 | HINOVA PHARMACEUTICALS INC.: Q1 2024 Earnings Release (Projected) |
| 26/04/2024 | BEIJING SUN-NOVO PHARMACEUTICAL RESEARCH CO., LTD.: Q4 2023 Earnings Release |
| 26/04/2024 | CHEMPARTNER PHARMATECH CO., LTD.: Q4 2023 Earnings Release |
| 25/04/2024 04:30 pm | MORPHIC HOLDING, INC.: Q1 2024 Earnings Release |
| 25/04/2024 11:30 am | PURETECH HEALTH PLC: Q4 2023 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- IPH Stock
- Calendar Innate Pharma
